{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Pulsed Field Ablation and PAS; TRIDENT &amp; Antihypertensive Polypharmacy; NOBLE and PCI vs. CABG","description":" In this week\u2019s View, Dr. Eagle\u202flooks at&amp;nbsp;the NOBLE trial&amp;nbsp;evaluating&amp;nbsp;whether&amp;nbsp;percutaneous coronary intervention (PCI)&amp;nbsp;or&amp;nbsp;coronary artery bypass grafting (CABG)&amp;nbsp;is best&amp;nbsp;for patients with unprotected left main coronary artery disease (CAD).&amp;nbsp;He then\u202fexplores&amp;nbsp;a report&amp;nbsp;highlighting&amp;nbsp;nanosecond pulsed field ablation (nsPFA) and its safety and efficacy at one year for paroxysmal atrial fibrillation.&amp;nbsp;Finally, Dr. Eagle presents a summary of the TRIDENT trial, which compares a triple\u2011pill antihypertensive strategy with conventional therapy and finds a positive impact on hypertension management and stroke risk following intracerebral hemorrhage.&amp;nbsp;   Subscribe to Eagle\u2019s Eye View\u202f\u202f&amp;nbsp;   &amp;nbsp;&amp;nbsp;&amp;nbsp;  ","author_name":"Eagle's Eye View: Your Weekly CV Update From ACC.org","author_url":"http:\/\/www.acc.org","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41145185\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/201542210"}